

# Asa Petersen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/233350/publications.pdf>

Version: 2024-02-01

79  
papers

3,660  
citations

147801

31  
h-index

138484

58  
g-index

84  
all docs

84  
docs citations

84  
times ranked

3915  
citing authors

#	ARTICLE	IF	CITATIONS
1	Orexin loss in Huntington's disease. <i>Human Molecular Genetics</i> , 2005, 14, 39-47.	2.9	246
2	Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. <i>European Neuropsychopharmacology</i> , 2007, 17, 573-579.	0.7	176
3	Hypothalamic endocrine aspects in Huntington's disease. <i>European Journal of Neuroscience</i> , 2006, 24, 961-967.	2.6	167
4	Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice. <i>Neurobiology of Disease</i> , 2005, 20, 744-751.	4.4	158
5	Eating and hypothalamus changes in behavioral variant frontotemporal dementia. <i>Annals of Neurology</i> , 2011, 69, 312-319.	5.3	158
6	Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. <i>Brain</i> , 2008, 132, 919-932.	7.6	135
7	The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient $\beta$ -cell mass and exocytosis. <i>Human Molecular Genetics</i> , 2005, 14, 565-574.	2.9	129
8	Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. <i>Human Molecular Genetics</i> , 2006, 15, 1713-1721.	2.9	122
9	Increased metabolism in the R6/2 mouse model of Huntington's disease. <i>Neurobiology of Disease</i> , 2008, 29, 41-51.	4.4	114
10	Sex differences in a transgenic rat model of Huntington's disease: decreased $17\beta$ -estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. <i>Human Molecular Genetics</i> , 2008, 17, 2595-2609.	2.9	114
11	Hypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 1033-1041.	1.9	113
12	Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 2.	2.9	113
13	Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. <i>Acta Neuropathologica</i> , 2010, 120, 777-788.	7.7	93
14	Testicular degeneration in Huntington disease. <i>Neurobiology of Disease</i> , 2007, 26, 512-520.	4.4	90
15	Mutant Huntingtin Causes Metabolic Imbalance by Disruption of Hypothalamic Neurocircuits. <i>Cell Metabolism</i> , 2011, 13, 428-439.	16.2	90
16	Evidence for Dysfunction of the Nigrostriatal Pathway in the R6/1 Line of Transgenic Huntington's Disease Mice. <i>Neurobiology of Disease</i> , 2002, 11, 134-146.	4.4	86
17	Increased thirst and drinking in Huntington's disease and the R6/2 mouse. <i>Brain Research Bulletin</i> , 2008, 76, 70-79.	3.0	82
18	Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. <i>Neurobiology of Disease</i> , 2010, 40, 531-543.	4.4	74

#	ARTICLE	IF	CITATIONS
19	Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease. <i>Human Molecular Genetics</i> , 2013, 22, 3485-3497.	2.9	67
20	Huntingtin Aggregation Impairs Autophagy, Leading to Argonaute-2 Accumulation and Global MicroRNA Dysregulation. <i>Cell Reports</i> , 2018, 24, 1397-1406.	6.4	66
21	Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease. <i>European Journal of Neuroscience</i> , 2005, 22, 1541-1546.	2.6	61
22	Increased orexin levels in the cerebrospinal fluid the first year after a suicide attempt. <i>Journal of Affective Disorders</i> , 2009, 113, 179-182.	4.1	61
23	Increased numbers of orexin/hypocretin neurons in a genetic rat depression model. <i>Neuropeptides</i> , 2011, 45, 401-406.	2.2	59
24	mHTT Seeding Activity: A Marker of Disease Progression and Neurotoxicity in Models of Huntington's Disease. <i>Molecular Cell</i> , 2018, 71, 675-688.e6.	9.7	50
25	Maintenance of Susceptibility to Neurodegeneration Following Intrastratial Injections of Quinolinic Acid in a New Transgenic Mouse Model of Huntington's Disease. <i>Experimental Neurology</i> , 2002, 175, 297-300.	4.1	47
26	Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8765-E8774.	7.1	47
27	Hypothalamic and Limbic System Changes in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2012, 1, 5-16.	1.9	41
28	Hypothalamic and Neuroendocrine Changes in Huntingtons Disease. <i>Current Drug Targets</i> , 2010, 11, 1237-1249.	2.1	41
29	Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. <i>Neurobiology of Disease</i> , 2017, 97, 179-188.	4.4	40
30	Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. <i>European Journal of Neuroscience</i> , 2001, 14, 1425-1435.	2.6	39
31	Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic $\alpha$ 2-receptor levels in a transgenic Huntington's disease rat model. <i>Behavioural Brain Research</i> , 2009, 205, 175-182.	2.2	35
32	Increased levels of cocaine and amphetamine regulated transcript in two animal models of depression and anxiety. <i>Neurobiology of Disease</i> , 2009, 34, 375-380.	4.4	32
33	Cerebrospinal fluid levels of orexin are not a clinically useful biomarker for Huntington disease. <i>Clinical Genetics</i> , 2006, 70, 78-79.	2.0	31
34	Selective loss of oxytocin and vasopressin in the hypothalamus in early Huntington disease: a case study. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 843-848.	3.2	31
35	SIRT1 is increased in affected brain regions and hypothalamic metabolic pathways are altered in Huntington disease. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 361-379.	3.2	31
36	Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 979-989.	3.2	31

#	ARTICLE	IF	CITATIONS
37	Volumetric Analysis of the Hypothalamus in Huntington Disease Using 3T MRI: The IMAGE-HD Study. PLoS ONE, 2015, 10, e0117593.	2.5	30
38	Subjective sleep problems in Huntington's disease: A pilot investigation of the relationship to brain structure, neurocognitive, and neuropsychiatric function. Journal of the Neurological Sciences, 2016, 364, 148-153.	0.6	29
39	The Role of Hypothalamic Pathology for Non-Motor Features of Huntington's Disease. Journal of Huntington's Disease, 2019, 8, 375-391.	1.9	29
40	Reduced CSF CART in dementia with Lewy bodies. Neuroscience Letters, 2009, 453, 104-106.	2.1	26
41	Huntington's Disease – New Perspectives Based on Neuroendocrine Changes in Rodent Models. Neurodegenerative Diseases, 2009, 6, 154-164.	1.4	25
42	Islet $\beta$ -cell area and hormone expression are unaltered in Huntington's disease. Histochemistry and Cell Biology, 2008, 129, 623-629.	1.7	24
43	Escitalopram reduces increased hippocampal cytotogenesis in a genetic rat depression model. Neuroscience Letters, 2008, 436, 305-308.	2.1	24
44	Microstructural white matter alterations and hippocampal volumes are associated with cognitive deficits in craniopharyngioma. European Journal of Endocrinology, 2018, 178, 577-587.	3.7	24
45	Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors. European Journal of Neurology, 2010, 17, 456-460.	3.3	22
46	Low dietary protein content alleviates motor symptoms in mice with mutant dynactin/dynein-mediated neurodegeneration. Human Molecular Genetics, 2015, 24, 2228-2240.	2.9	22
47	Nortriptyline mediates behavioral effects without affecting hippocampal cytotogenesis in a genetic rat depression model. Neuroscience Letters, 2009, 451, 148-151.	2.1	21
48	Maintenance of Basal Levels of Autophagy in Huntington's Disease Mouse Models Displaying Metabolic Dysfunction. PLoS ONE, 2013, 8, e83050.	2.5	21
49	Laminin $\beta$ 1 reduces muscular dystrophy in dy <sup>2J</sup> mice. Matrix Biology, 2018, 70, 36-49.	3.6	19
50	Detailed assessment of hypothalamic damage in craniopharyngioma patients with obesity. International Journal of Obesity, 2019, 43, 533-544.	3.4	19
51	Cocaine- and amphetamine-regulated transcript is increased in Huntington disease. Movement Disorders, 2007, 22, 1952-1954.	3.9	18
52	Metabolic and behavioral effects of mutant huntingtin deletion in Sim1 neurons in the BACHD mouse model of Huntington's disease. Scientific Reports, 2016, 6, 28322.	3.3	18
53	Expression of Mutant Huntingtin in Leptin Receptor-Expressing Neurons Does Not Control the Metabolic and Psychiatric Phenotype of the BACHD Mouse. PLoS ONE, 2012, 7, e51168.	2.5	18
54	Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington's Disease: increased NPY levels and differential degradation of the NPY <sub>30</sub> fragment. Journal of Neurochemistry, 2016, 137, 820-837.	3.9	17

#	ARTICLE	IF	CITATIONS
55	Hypothalamic overexpression of mutant huntingtin causes dysregulation of brown adipose tissue. <i>Scientific Reports</i> , 2015, 5, 14598.	3.3	16
56	Effects of Deletion of Mutant Huntingtin in Steroidogenic Factor 1 Neurons on the Psychiatric and Metabolic Phenotype in the BACHD Mouse Model of Huntington Disease. <i>PLoS ONE</i> , 2014, 9, e107691.	2.5	16
57	Associations between Metabolic Risk Factors and the Hypothalamic Volume in Childhood Leukemia Survivors Treated with Cranial Radiotherapy. <i>PLoS ONE</i> , 2016, 11, e0147575.	2.5	14
58	Early white matter pathology in the fornix of the limbic system in Huntington disease. <i>Acta Neuropathologica</i> , 2021, 142, 791-806.	7.7	13
59	Huntington's disease: The mystery unfolds?. <i>International Review of Neurobiology</i> , 2002, 53, 315-339.	2.0	12
60	Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors. <i>European Journal of Neuroscience</i> , 2012, 36, 2789-2800.	2.6	11
61	Hypothalamic expression of huntingtin causes distinct metabolic changes in Huntington's disease mice. <i>Molecular Metabolism</i> , 2022, 57, 101439.	6.5	11
62	Quantification of Total and Mutant Huntingtin Protein Levels in Biospecimens Using a Novel alphaLISA Assay. <i>ENeuro</i> , 2018, 5, ENEURO.0234-18.2018.	1.9	10
63	Euploidy in somatic cells from R6/2 transgenic Huntington's disease mice. <i>BMC Cell Biology</i> , 2005, 6, 34.	3.0	8
64	The psychopharmacology of Huntington disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 165, 179-189.	1.8	8
65	Imbalance of the oxytocin-vasopressin system contributes to the neuropsychiatric phenotype in the BACHD mouse model of Huntington disease. <i>Psychoneuroendocrinology</i> , 2020, 119, 104773.	2.7	8
66	Decreased CSF oxytocin relates to measures of social cognitive impairment in Huntington's disease patients. <i>Parkinsonism and Related Disorders</i> , 2022, 99, 23-29.	2.2	8
67	Cocaine and amphetamine regulated transcript (CART) in suicide attempters. <i>Psychiatry Research</i> , 2008, 158, 117-122.	3.3	7
68	Microstructure alterations in the hypothalamus in cranially radiated childhood leukaemia survivors but not in craniopharyngioma patients unaffected by hypothalamic damage. <i>Clinical Endocrinology</i> , 2017, 87, 359-366.	2.4	7
69	Thermoregulation in amyotrophic lateral sclerosis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 157, 749-760.	1.8	7
70	Transthyretin in cerebrospinal fluid from suicide attempters. <i>Journal of Affective Disorders</i> , 2008, 109, 205-208.	4.1	6
71	Analysis of Nonmotor Features in Murine Models of Huntington Disease. , 2015, , 583-602.		6
72	Thermoregulatory disorders in Huntington disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 157, 761-775.	1.8	6

#	ARTICLE	IF	CITATIONS
73	Brain white matter lesions are associated with reduced hypothalamic volume and cranial radiotherapy in childhood-onset craniopharyngioma. <i>Clinical Endocrinology</i> , 2021, 94, 48-57.	2.4	3
74	IKK $\beta$ signaling mediates metabolic changes in the hypothalamus of a Huntington disease mouse model. <i>IScience</i> , 2022, 25, 103771.	4.1	3
75	Effects of excitotoxicity in the hypothalamus in transgenic mouse models of Huntington disease. <i>Heliyon</i> , 2021, 7, e07808.	3.2	2
76	Effects of mutant huntingtin inactivation on Huntington disease-related behaviours in the BACHD mouse model. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 564-578.	3.2	1
77	F05...The experience of a genetic brain disorder: cultural and social perspectives on huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, A24.1-A24.	1.9	0
78	F01...Establishment of novel assays for quantification of full-length wild-type and mutant huntingtin by using the alphaLisa technology. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, A21.2-A21.	1.9	0
79	A15...Hypothalamic expression of huntingtin causes distinct metabolic changes in the R6/2 and bachd mouse models of huntington's disease. , 2021, , .		0